CO2019005169A2 - Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus - Google Patents
Constructos de vacuna y sus usos contra infecciones causadas por staphylococcusInfo
- Publication number
- CO2019005169A2 CO2019005169A2 CONC2019/0005169A CO2019005169A CO2019005169A2 CO 2019005169 A2 CO2019005169 A2 CO 2019005169A2 CO 2019005169 A CO2019005169 A CO 2019005169A CO 2019005169 A2 CO2019005169 A2 CO 2019005169A2
- Authority
- CO
- Colombia
- Prior art keywords
- polypeptide
- seq
- amino acid
- set forth
- nos
- Prior art date
Links
- 241000191940 Staphylococcus Species 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 22
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 22
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 22
- 150000001413 amino acids Chemical class 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 230000004927 fusion Effects 0.000 abstract 3
- 239000011230 binding agent Substances 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 101100211536 Staphylococcus aureus (strain COL) SACOL2365 gene Proteins 0.000 abstract 1
- 101100227953 Staphylococcus aureus (strain COL) fur gene Proteins 0.000 abstract 1
- 101100404789 Staphylococcus aureus (strain COL) nikC gene Proteins 0.000 abstract 1
- 101100422138 Staphylococcus aureus (strain COL) splC gene Proteins 0.000 abstract 1
- 241000344863 Staphylococcus aureus subsp. aureus COL Species 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411120P | 2016-10-21 | 2016-10-21 | |
| PCT/CA2017/051253 WO2018072031A1 (en) | 2016-10-21 | 2017-10-20 | Vaccine constructs and uses thereof against staphylococcus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019005169A2 true CO2019005169A2 (es) | 2019-08-09 |
Family
ID=62018642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0005169A CO2019005169A2 (es) | 2016-10-21 | 2019-05-21 | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11324815B2 (OSRAM) |
| EP (1) | EP3529260A4 (OSRAM) |
| JP (2) | JP7181208B2 (OSRAM) |
| KR (1) | KR20190082229A (OSRAM) |
| CN (1) | CN109843910A (OSRAM) |
| AR (1) | AR109847A1 (OSRAM) |
| AU (2) | AU2017346974B2 (OSRAM) |
| BR (1) | BR112019007796A2 (OSRAM) |
| CA (1) | CA3037070A1 (OSRAM) |
| CL (1) | CL2019001048A1 (OSRAM) |
| CO (1) | CO2019005169A2 (OSRAM) |
| CR (1) | CR20190249A (OSRAM) |
| DO (1) | DOP2019000102A (OSRAM) |
| IL (1) | IL265869A (OSRAM) |
| MX (2) | MX2019004539A (OSRAM) |
| MY (1) | MY195369A (OSRAM) |
| NZ (1) | NZ751880A (OSRAM) |
| PE (1) | PE20191320A1 (OSRAM) |
| PH (1) | PH12019500843A1 (OSRAM) |
| RU (2) | RU2022100889A (OSRAM) |
| SG (2) | SG10201912431XA (OSRAM) |
| TW (1) | TW201819402A (OSRAM) |
| UY (1) | UY37448A (OSRAM) |
| WO (1) | WO2018072031A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113777317A (zh) * | 2020-06-09 | 2021-12-10 | 首都医科大学附属北京世纪坛医院 | 尿液主穹隆蛋白及其多肽片段在烧伤中的应用 |
| US20220185852A1 (en) * | 2020-12-11 | 2022-06-16 | Bayer Animal Health Gmbh | Methods and compositions for improved production of an antigen for use in an s. aureus vaccine |
| WO2026014994A1 (ko) * | 2024-07-12 | 2026-01-15 | 주식회사 더윤헬스텍 | 젖소 유방염 유래 대장균 또는 황색 포도알균 변이주 및 이를 포함하는 백신 조성물 |
| US12161970B1 (en) | 2024-08-09 | 2024-12-10 | Jiaxing Research Institute, Zhejiang University | CO2 desorption system suitable for limited space in complex sailing region and flexible control method |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1288774C (en) | 1985-01-07 | 1991-09-10 | Deborah A. Eppstein | 1,2-dialkoxy-w-trialkylammonium cationic surfactants |
| US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
| US7060458B1 (en) | 1997-08-14 | 2006-06-13 | Wyeth | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US6380370B1 (en) * | 1997-08-14 | 2002-04-30 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US6833134B2 (en) | 2000-06-12 | 2004-12-21 | University Of Saskacthewan | Immunization of dairy cattle with GapC protein against Streptococcus infection |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| MXPA05005045A (es) | 2002-11-12 | 2005-07-01 | Brigham & Womens Hospital | Vacuna de polisacarido para infecciones estafilococicas. |
| CN1569893A (zh) | 2003-07-21 | 2005-01-26 | 中国人民解放军军事医学科学院基础医学研究所 | 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途 |
| RU2419628C2 (ru) | 2004-09-22 | 2011-05-27 | ГлаксоСмитКлайн Байолоджикалз с.а. | Иммуногенная композиция для применения в вакцинации против стафилококков |
| BRPI0516974A (pt) * | 2004-10-21 | 2008-09-30 | Wyeth Corp | composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis |
| KR100729954B1 (ko) | 2004-12-01 | 2007-06-20 | 주식회사 엘지생명과학 | Ｓｅｃ１ 변이 단백질의 제형 및 그것의 제형화 방법 |
| CA2667788A1 (en) | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
| EP2411046B1 (en) | 2009-03-23 | 2017-12-06 | Epitopix, LLC | Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use |
| NZ612315A (en) | 2009-04-14 | 2014-10-31 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| CA2792956C (en) * | 2010-03-17 | 2021-11-16 | Socpra - Sciences Et Genie, S.E.C. | Bacterial vaccine components from staphylococcus aureus and uses thereof |
| BR112013032774B1 (pt) | 2011-06-19 | 2020-05-05 | Univ New York | composições compreendendo proteína luke isolada ou polipeptídeo da mesma, uma proteína lukd isolada ou polipeptídeo da mesma ou sua combinação, bem como seu uso |
-
2017
- 2017-10-20 BR BR112019007796A patent/BR112019007796A2/pt not_active IP Right Cessation
- 2017-10-20 JP JP2019542759A patent/JP7181208B2/ja active Active
- 2017-10-20 US US16/337,457 patent/US11324815B2/en active Active
- 2017-10-20 RU RU2022100889A patent/RU2022100889A/ru unknown
- 2017-10-20 MY MYPI2019002159A patent/MY195369A/en unknown
- 2017-10-20 TW TW106136089A patent/TW201819402A/zh unknown
- 2017-10-20 CA CA3037070A patent/CA3037070A1/en active Pending
- 2017-10-20 PE PE2019000844A patent/PE20191320A1/es unknown
- 2017-10-20 AU AU2017346974A patent/AU2017346974B2/en not_active Ceased
- 2017-10-20 RU RU2019115303A patent/RU2766354C2/ru active
- 2017-10-20 CR CR20190249A patent/CR20190249A/es unknown
- 2017-10-20 WO PCT/CA2017/051253 patent/WO2018072031A1/en not_active Ceased
- 2017-10-20 SG SG10201912431XA patent/SG10201912431XA/en unknown
- 2017-10-20 CN CN201780064991.1A patent/CN109843910A/zh active Pending
- 2017-10-20 NZ NZ751880A patent/NZ751880A/en unknown
- 2017-10-20 AR ARP170102922A patent/AR109847A1/es not_active Application Discontinuation
- 2017-10-20 SG SG11201901483QA patent/SG11201901483QA/en unknown
- 2017-10-20 KR KR1020197014191A patent/KR20190082229A/ko not_active Abandoned
- 2017-10-20 UY UY0001037448A patent/UY37448A/es unknown
- 2017-10-20 EP EP17863203.0A patent/EP3529260A4/en active Pending
- 2017-10-20 MX MX2019004539A patent/MX2019004539A/es unknown
-
2019
- 2019-04-07 IL IL265869A patent/IL265869A/en unknown
- 2019-04-16 PH PH12019500843A patent/PH12019500843A1/en unknown
- 2019-04-17 MX MX2023001219A patent/MX2023001219A/es unknown
- 2019-04-17 DO DO2019000102A patent/DOP2019000102A/es unknown
- 2019-04-17 CL CL2019001048A patent/CL2019001048A1/es unknown
- 2019-05-21 CO CONC2019/0005169A patent/CO2019005169A2/es unknown
-
2022
- 2022-04-05 US US17/713,683 patent/US20220288183A1/en not_active Abandoned
- 2022-06-28 AU AU2022204585A patent/AU2022204585A1/en not_active Abandoned
- 2022-11-16 JP JP2022183528A patent/JP2023025066A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021226436A8 (en) | Optimized nucleotide sequences encoding sars-cov-2 antigens | |
| CL2019001048A1 (es) | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus. | |
| AR086078A1 (es) | Proteinas de fusion y vacunas de combinacion | |
| MX2024002398A (es) | Proteinas de fusion gdf15 y usos de estas. | |
| CO2020009402A2 (es) | Proteínas de fusión fc il-22 y métodos de uso | |
| CY1118331T1 (el) | Χιμαιρικα πολυπεπτιδια και η χρηση τους στην εκριζωση φορειας βακτηριων | |
| PT2121731E (pt) | Vacinas peptídicas para cancros que expressam antigénios associados a tumores | |
| AR083839A1 (es) | Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos | |
| PE20220960A1 (es) | Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros | |
| CO6731074A2 (es) | Composición vacunal para el control de las infestaciones por ectoparásitos | |
| CY1125681T1 (el) | Εμβολια κατα του ιου της γριπης και χρησεις αυτων | |
| AR083533A1 (es) | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe | |
| PE20170955A1 (es) | Nuevas proteinas inhibidoras de insectos | |
| MX2017008563A (es) | Novedoso bacteriófago esc-cop-1 de e. coli tipo f18 productora de toxina shiga y su uso para inhibir la proliferación de e. coli tipo f18 productora de toxina shiga. | |
| MX420767B (es) | Proteina de union al factor h modificada | |
| CR20170507A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos. | |
| AR100824A1 (es) | Complejo de poliproteínas inmunogénicas de m. hyopneumoniae, gen sintético codificante del complejo de proliproteínas inmunogénicas de m. hyopneumoniae, composición antigénica, proceso de obtención de un complejo de poliproteínas inmunogénicas de m. hyopneumoniae, uso de una composición con base en el complejo de poliproteínas inmunogénicas de m. hyopneumoniae | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
| MX2018001298A (es) | Agente inductor de inmunidad. | |
| CO6362049A2 (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo | |
| MX348934B (es) | Secuencias de aminoacidos para el control de patogenos. | |
| NO20085201L (no) | Rekombinante novirhabdoviruser og deres anvendelse | |
| BR112022010228A2 (pt) | Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas | |
| CL2017002972A1 (es) | Péptido anti microbiano del tipo nk-lisina, para el control de agentes patógenos y su uso como adyuvante molecular. | |
| AR056782A1 (es) | Uso de polinucleotidos armadillo repeat (arm1) para lograr una resitencia contra agentes patogenos en plantas |